Verastem Inc Cash Flow Conversion Efficiency
Verastem Inc cash flow conversion efficiency. Based on the latest financial reports, Verastem Inc (VSTM) has a cash flow conversion efficiency ratio of -0.878x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.91 Million) by net assets ($49.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Verastem Inc (2010–2025)
Cash flow conversion efficiency of Verastem Inc from 2010 to 2025. This chart illustrates how Verastem Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VSTM stock price for real-time trading data and today's change.
Verastem Inc Cash Flow Conversion Ratio Explained
Verastem Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Verastem Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verastem Inc ranked by their cash flow conversion efficiency. Also see VSTM stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AhnLab Inc
KQ:053800
|
0.062x |
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
0.045x |
|
Shanghai Join Buy Co Ltd
SHG:600838
|
0.003x |
|
MAS Real Estate Inc
JSE:MSP
|
0.001x |
|
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
|
-0.019x |
|
Lions Gate Entertainment Corp
NYSE:LGF-A
|
0.760x |
|
Viglacera Corp JSC
VN:VGC
|
0.042x |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
0.031x |
Annual Cash Flow Conversion Efficiency for Verastem Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Verastem Inc from 2010 to 2025. Review how much free cash does Verastem Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.20 Million | $-137.51 Million | -2.404x | -166.30% |
| 2024-12-31 | $-28.89 Million | $-104.77 Million | 3.626x | +340.63% |
| 2023-12-31 | $57.37 Million | $-86.46 Million | -1.507x | -12.16% |
| 2022-12-31 | $47.39 Million | $-63.67 Million | -1.344x | -119.88% |
| 2021-12-31 | $87.56 Million | $-53.50 Million | -0.611x | -110.22% |
| 2020-12-31 | $115.27 Million | $-33.51 Million | -0.291x | +98.49% |
| 2019-12-31 | $7.17 Million | $-138.52 Million | -19.308x | -3120.84% |
| 2018-12-31 | $124.30 Million | $-74.52 Million | -0.599x | +39.66% |
| 2017-12-31 | $57.68 Million | $-57.31 Million | -0.994x | -143.62% |
| 2016-12-31 | $72.30 Million | $-29.48 Million | -0.408x | +8.28% |
| 2015-12-31 | $102.47 Million | $-45.56 Million | -0.445x | -6.95% |
| 2014-12-31 | $88.77 Million | $-36.90 Million | -0.416x | -85.61% |
| 2013-12-31 | $117.45 Million | $-26.30 Million | -0.224x | +10.35% |
| 2012-12-31 | $90.47 Million | $-22.60 Million | -0.250x | -131.48% |
| 2011-12-31 | $-12.77 Million | $-10.13 Million | 0.794x | +878.28% |
| 2010-12-31 | $3.24 Million | $-330.00K | -0.102x | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more